Skip Navigation

Journal of Antimicrobial Chemotherapy 2005 55(Supplement 2):ii15-ii20; doi:10.1093/jac/dki005
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Malabarba, A.
Right arrow Articles by Goldstein, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malabarba, A.
Right arrow Articles by Goldstein, B. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Supplement

Origin, structure, and activity in vitro and in vivo of dalbavancin

Adriano Malabarba1 and Beth P. Goldstein2,*

1 Vicuron Pharmaceuticals, Via R. Lepetit 34-21040, Gerenzano, Varese, Italy; 2 Vicuron Pharmaceuticals, King of Prussia, PA, USA

* Corresponding author. Tel: +1-610-491-2209; Fax: +1-610-491-2229; Email: bgoldstein{at}vicuron.com

Dalbavancin is a novel semi-synthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin. Chemical modification of natural glycopeptides has produced compounds with more potent antimicrobial activity and longer t1/2, while maintaining an excellent safety profile. Dalbavancin, prepared from a teicoplanin-like glycopeptide, has better activity, in vitro and in animal infection models, than vancomycin and teicoplanin. In particular, dalbavancin has excellent activity against staphylococci, including coagulase-negatives. A unique feature of dalbavancin is its pharmacokinetics, characterized by a long elimination t1/2 in humans which makes a once-weekly dosing regimen feasible. Dalbavancin recently completed Phase 3 clinical trials in skin and skin structure infection.

Keywords: glycopeptides , structure–activity relationships , Gram-positive , staphylococci


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. Bailey and K. M. Summers
Dalbavancin: A new lipoglycopeptide antibiotic
Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 599 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. J. Attwood and K. L. LaPlante
Telavancin: A novel lipoglycopeptide antimicrobial agent
Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
T. R. Fritsche, R. P. Rennie, B. P. Goldstein, and R. N. Jones
Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms.
J. Clin. Microbiol., August 1, 2006; 44(8): 2988 - 2990.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. G. Mariani, H. S. Sader, and R. N. Jones
Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy
J. Antimicrob. Chemother., August 1, 2006; 58(2): 481 - 483.
[Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
R. N. Jones, H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan
Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
J. Clin. Microbiol., July 1, 2006; 44(7): 2622 - 2625.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S.-W. Lin, P. L Carver, and D. D DePestel
Dalbavancin: A New Option for the Treatment of Gram-Positive Infections
Ann. Pharmacother., March 1, 2006; 40(3): 449 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum
Antipneumococcal Activity of Dalbavancin Compared to Other Agents
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.